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Abstract 
UK national guidelines recommend that older people at risk of falling should have their 
fracture risk assessed and acted upon. People with cognitive impairment are more likely to 
sustain a fracture than their cognitively intact peers. We assessed the fracture risk of 79 
memory clinic attendees and compared their actual management with guidelines. Despite 
reporting 57 falls in the last year, only 36% of those who would be recommended 
antiresportive treatment were prescribed it and a DEXA scan was performed in only 13% 
where it would be recommended. These findings highlight an important deficit in fracture risk 
assessment which should inform future interventions. 
 
1. Introduction 
There are an estimated 850,000 people in the United Kingdom (UK) living with dementia. 
This figure is expected to exceed one million by 2025 and two million by 20511. People with 
cognitive impairment have at least a two-fold risk of falling compared to their cognitively 
intact peers 2,3. In addition, having fallen, they are at higher risk of sustaining a fracture, 
particularly a hip fracture 4 and have a poorer recovery following a fracture than the general 
population5. Evidenced-based interventions that reduce the risk of fracture are therefore to 
be welcomed. 
NICE recommends that fracture risk assessment be considered in all women aged over 65, 
all men aged over 75 and younger people (>50yrs) in the presence of risk factors6. The 
presence of cognitive impairment is a risk factor for falling and fracturing7. Therefore, a 
suspected or diagnosed cognitive impairment should ideally prompt a fracture risk 
assessment, which should then be acted upon.  
FRAX® is a fracture risk assessment tool used to evaluate a patient’s probability of fracture in 
the next 10 years based on individual patient models of clinical risk factors and femoral neck 
bone mineral density (BMD)8. A patient’s FRAX® scores can be used to identify one of three 
recommended managements based on National Osteoporosis Guideline Group (NOGG) 
advice: lifestyle advice and reassurance for those at low risk; measurement of BMD using 
DEXA and recalculation of FRAX® for those at medium risk; and treatment for those at high 
risk9.  
This project set out to assess whether memory clinic attendees had had their fracture risk 
identified and acted upon in accordance with NOGG guidelines. 
2. Materials and methods 
The Research Institute for the Care of Older People (RICE) provides the National Health 
Service (NHS) memory clinic for the population of Bath and North East Somerset in the UK, 
a mix of rural and urban areas. People attending the RICE Memory Clinic to see a physician 
from the 1st of February until the 12th of March 2018 (6 weeks) were included in this study. 
The 10-year-risks of major osteoporotic fractures and hip fractures were calculated using 
FRAX® by their physician (TW (geriatrician), CW (GP/memory clinic physician) or JH (old-
age psychiatrist)) as part of routine care. TW is a geriatrician experienced in bone health 
management and provided an update and training in the use of fracture risk assessment 
tools. NOGG recommendations based on this assessment were documented. Attendees’ 
current bone treatment plan, falls history and any historic DEXA scans were documented. 
These collected data, together with demographic information, cognitive diagnoses and Mini-
Mental-State Examination10 scores were combined and anonymised. Recommended 
fracture risk treatment and actual treatment were then compared. 
3. Results 
Data were available from 79 attendees. Table 1 summarizes the results.  
Table 1 Fracture risk, cognitive diagnoses, recommended and enacted treatments 
Demographics All Male Female 
N 79 32 47 
Mean Age (SD) 83 (5.9) 81 (5.5) 84 (6.0) 
Mean MMSE (SD) 21 (4.8) 21 (4.9) 21 (4.7) 
Cognitive diagnosis  
Alzheimer’s Disease dementia 23 (29%) 7 (22%) 16 (34%) 
Vascular dementia 10 (13%) 3 (9%) 7 (15%) 
Mixed dementia 13 (16%) 8 (25%) 5 (11%) 
Fronto-temporal degeneration 4 (5%) 2 (6%) 2 (4%) 
Dementia with Lewy bodies 1 (1%) 1 (3%) 0 (-) 
Mild Cognitive Impairment 13 (16%) 6 (19%) 7 (15%) 
Other 3 (4%) 1 (3%) 2 (4%) 
Unspecified dementia 12 (15%) 4 (13%) 8 (17%) 
Mean 10-year risk % (SD) 
Major osteoporotic fracture 21% (12) 11% (7) 28% (10) 
Hip fracture 12% (9) 6% (4) 15% (10) 
Comparison of recommended and actual management 
Lifestyle advice 17 (22%) 17 (63%) 0 (0%) 
DEXA recommended 30 (38%) 9 (28%) 21 (45%) 
DEXA carried out 4 (5%) 2 (6%) 2 (3%) 
DEXA proportion of recommended 13% 22% 10% 
Treatment recommended 28 (35%) 2 (6%) 26 (55%) 
Treatment prescribed 10 (13%) 1 (3%) 9 (19%) 
Treatment proportion of 
recommended 
36% 50% 35% 
Treatments prescribed    
Calcium/vitamin D 26 (33%) 3 (9%) 23 (49%) 
Oral bisphosphonate 8 (10%) 1 (3%) 7 (15%) 
IV bisphosphonate 1 (1%) - 1 (2%) 
Denosumab 1 (1%) - 1 (2%) 
 
4. Discussion 
The fracture risk management of this population of memory clinic attendees did not follow 
the NOGG recommendations. Of the 28 attendees where guidelines recommend treatment 
be started, only ten (36%) were on recommended therapy. Only two out of 21 (10%) female 
attendees had undergone the recommended DEXA scan. Fifty-eight (73%) patients were 
recommended either to start treatment or undergo a DEXA scan based on their FRAX® 
scores, but only 14 of those had had this recommendation acted upon.   
The participants in this project were typical of the population who attend memory clinics in 
England, who are typically White British, less deprived, and have an MMSE of <24 11. This is 
also in keeping with the population of Bath and North East Somerset 12. As such these 
findings are likely to be generalizable to other memory clinic populations. However, there 
were some limitations to the project which potentially affect the interpretation of the findings. 
The sample size was small and was carried out in only a single memory clinic over a time 
limited period. Data collection for the calculation of the FRAX® score relied on participants’ 
recall of a number of risk factors such as alcohol consumption and parental hip fracture. 
Where there was uncertainty it was assumed that a participant had not been exposed to the 
risk. This assumption tends to an under-estimate of the fracture risk. Missing data from two 
individuals, albeit a small proportion of the study population, led to them being excluded from 
the analysis. The medical staff working in this clinic were not typical of many UK memory 
clinics which are largely run by psychiatrists who may not have experience in fracture risk 
assessment. This potentially limits the management of fracture risk within a psychiatry led 
memory clinic. Assessment processes, however, could still highlight those most at risk and 
in need of appropriate treatment.  
We are unaware of any previous published data on fracture risk management in memory 
clinic populations in the UK. We are aware of one study that was carried out in Australia, 
where only 9.9% of memory clinic attendees who required treatment were on specific 
antiresorptive therapy 13. In the UK, of those presenting with a hip fracture in one series, only 
33% of those who required treatment were receiving it 14; a similar level to that in this project. 
In a Portuguese study, despite national guidelines identifying 91.5% as requiring treatment, 
only 21.5% were actually on appropriate medication15. The reasons for this treatment gap 
are complex, multifactorial and in many cases unclear. To a degree it may relate to 
uncertainty over clinical responsibility for fracture risk and osteoporosis assessment which is 
often shared between primary and secondary care 14. Despite increasing publicity and 
updated guidance there has been a drop in prescription rates for anti-osteoporotic drugs in 
recent years, particularly amongst women 16. Unless this represents informed patient choice, 
or therapeutic breaks in treatment, it is concerning. Fear of the rarer side effects of 
bisphosphonates, such as the much publicised risk of atypical femoral fractures, by both 
patient and physician, may be a contributing factor in this under-treatment 17. Even when 
treatment is recommended, the majority of those prescribed weekly oral bisphosphonates 
stop taking them within one year 18. This constitutes a major challenge and needs to be 
understood in order to provide effective and acceptable strategies to improve assessment 
and, where appropriate, uptake of treatment. Of course, shared decision-making involves the 
integration of evidence and values, which may be more difficult as cognitive impairment 
advances, but should still be pursued 14,19. 
Nevertheless, there is good quality research evidence to support the use of medication in 
osteoporosis for fracture prevention20 and this underpins current guidelines on fracture risk 
reduction 9,15. People with cognitive impairment are more likely to fall and sustain a fracture 
than their cognitively intact peers and they are more likely to have poorer outcomes following 
a fracture5. As such FRAX® may be under-estimating their risk of fracture. Different 
thresholds for initiating medication to reduce fracture risk may apply to this group. However, 
the evidence from this project highlights that at present treatment levels do not even 
approach current recommendations. Before dementia-specific recommendations can be 
made, better implementation of current guidance is required. Given the increased risk of 
fracture in people with cognitive impairment, referral to a memory service provides the 
opportunity to highlight this risk and intervene. We intend to use these findings to support 
further exploratory work to identify barriers to risk assessment and treatment 
implementation. Ultimately, we intend that these findings will support future work to test 
interventions that may improve treatment rates. 
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